Categories: News

IRLAB Announces Invitation to Presentation of the Interim Report for Q1 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

GOTHENBURG, SWEDEN / ACCESSWIRE / May 4, 2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)

IRLAB Therapeutics AB (publ) today announced that the company will hold a conference call in conjunction with the publication of the interim report for the first quarter, January-March 2022. The report will be published on Wednesday, May 11 at 07:45 CET.

The conference call will be held on May 11, 2022, at 10:30 CET where CEO Nicholas Waters and CFO Viktor Siewertz will comment the interim report for the first quarter, January-March 2022. The presentation will be held in English and followed by a Q&A session.

To participate in the conference call, please dial:
SE +46 850 558 369
UK +44 333 300 9260
US +1 631 913 1422

It is also possible to follow the presentation live on:
https://tv.streamfabriken.com/irlab-q1-2022

The presentation material will be in English and will be available in connection with the conference call at www.irlab.se, where the recorded version of the presentation will also be available afterwards.

For more information

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB discovers and develops novel treatments of Parkinson’s disease and other disorders of the brain. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, IRLAB entered an exclusive and worldwide license with Ipsen for the development and marketing of mesdopetam.

Through ISP, its proprietary research platform, IRLAB has discovered and developed all its experimental drug candidates and continues to discover innovative drug candidates for the treatment of disorders of the brain. In addition to IRLAB’s strong clinical pipeline, IRLAB runs several preclinical programs with IRL942 and IRL757 currently in development towards Phase I. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.

Attachments

IRLAB announces invitation to presentation of the interim report for Q1 2022

SOURCE: IRLAB Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/700108/IRLAB-Announces-Invitation-to-Presentation-of-the-Interim-Report-for-Q1-2022

Staff

Recent Posts

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),…

2 hours ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4…

4 hours ago

Healthcare Analytical Testing Services Market worth $12.48 billion by 2030 with 10.8% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 25, 2025 /PRNewswire/ -- The global Healthcare Analytical Testing Services Market,…

5 hours ago

Dynamic Infrastructure Partners with The Advocacy Partners to Accelerate AI-Driven Bridge Maintenance Across Florida

TALLAHASSEE, Fla., July 25, 2025 /PRNewswire/ -- Dynamic Infrastructure (diglobal.tech), the leading provider of AI-powered…

5 hours ago

Weekly Recap: 12 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's…

5 hours ago

Red Light Holland Selects Arch Public for Bitcoin Purchases on Recommendation from Advisor Scott Melker

Toronto, Ontario--(Newsfile Corp. - July 25, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE:…

8 hours ago